Sign In
Buy NEO
$10.14
+0.0200 (+0.198%)
At Close: Jun 03, 2026
AI-boosted medical diagnostics firm Tempus AI given 'buy' rating
02:27pm, Tuesday, 09'th Jul 2024
Tempus AI (NASDAQ:TEM), a provider of AI-enabled precision medicine, has been initiated with a 'buy' rating by Bank of America, which likes how the company combines a patient's molecular, clinical an
Fort Myers' Mayor to Proclaim June as NeoGenomics' Commitment to Cancer Month
08:00am, Thursday, 13'th Jun 2024
FORT MYERS, Fla.--(BUSINESS WIRE)--Fort Myers' Mayor, Kevin Anderson, will be proclaiming June as NeoGenomics' Commitment to Cancer Month.
NEO Battery Materials Forges Collaboration Agreement with Major South Korean Chemical Material Company, INNOX eco-M
08:30am, Tuesday, 11'th Jun 2024
TORONTO, June 11, 2024 (GLOBE NEWSWIRE) -- (T S X V : NBM) (OTC: NBMFF)
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at ASCO 2024 in Chicago (booth #31093).
NeoGenomics, Inc. (NEO) Q1 2024 Earnings Call Transcript
02:11pm, Tuesday, 30'th Apr 2024
NeoGenomics, Inc. (NASDAQ:NEO ) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - Chief Comm
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
11:31am, Tuesday, 30'th Apr 2024
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compar
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
09:41am, Tuesday, 30'th Apr 2024
NeoGenomics (NEO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
NeoGenomics Reports First Quarter 2024 Results
07:30am, Tuesday, 30'th Apr 2024
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. announced its first-quarter results for the period ended March 31, 2024.
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:07am, Tuesday, 23'rd Apr 2024
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics Announces Senior Leadership Promotions
07:05am, Thursday, 18'th Apr 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., announced two promotions within its senior leadership team, effective immediately.
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
07:00am, Tuesday, 09'th Apr 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its first quarter 2024 financial results on Tuesday, April 30, 2024.
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
08:30am, Wednesday, 27'th Mar 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data at AACR, showing its commitment to advancing cancer patient care through innovative research & development initiatives.
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
01:01pm, Wednesday, 20'th Mar 2024
NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
10:56am, Wednesday, 20'th Mar 2024
The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
